API
< Back to all clusters
[HEALTH] · Congo - Kinshasa, Kenya, Nigeria, Uganda · 23 sources

started · updated

WHO approves clinical trials for two new Ebola vaccines in DRC

The World Health Organization (WHO) has recommended expanding clinical trials in the Democratic Republic of the Congo to include two new vaccine candidates specifically targeting the Bundibugyo strain of the Ebola virus. The two candidates are ChAdOx1 BDBV, developed by the University of Oxford and the Serum Institute of India, and mRNA-1469, developed by Moderna.

The current outbreak, which was officially declared in May, is being driven by the Bundibugyo strain, for which there are currently no approved vaccines or specific treatments. While the Ervebo vaccine is being used in ongoing trials, it was developed for the Zaire strain and its effectiveness against Bundibugyo is unconfirmed.

According to the Africa Centres for Disease Control and Prevention (Africa CDC), the epidemic has resulted in 10,444 confirmed cases and more than 5,300 deaths, with the vast majority occurring in the DRC. The fatality rate is reported to exceed 50 percent. Cases have also been confirmed in Kenya, Uganda, and Nigeria. The clinical trials are being led by the DRC’s National Institute for Biomedical Research, with support from the WHO and other international partners. Researchers expect to obtain initial results from these vaccine trials in early 2027.

Entities

Democratic Republic of the Congo · Moderna · Tedros Adhanom Ghebreyesus · University of Oxford · World Health Organization

Claims

What the coverage asserts, and how many sources carry each claim.

Sources